Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders

Multiple Sclerosis

Volumn 15, Issue 2, 2009, Pages 189-192

  Petereit, H F ^a   Rubbert Roth, A ^b  

^a Heilig Geist Krankenhaus Koln   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Blood CSF barrier; Intrathecal Ig synthesis; Multiple sclerosis; Rituximab

Indexed keywords

IMMUNOGLOBULIN G; RITUXIMAB;

ADULT; ARTICLE; BLOOD CEREBROSPINAL FLUID BARRIER; BLOOD SAMPLING; CASE REPORT; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; FEMALE; HUMAN; LUMBAR PUNCTURE; MALE; MONONEUROPATHY MULTIPLEX; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE;

AGED; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; BLOOD-BRAIN BARRIER; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, INTRAVENOUS; LYMPHOCYTE COUNT; MALE; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA; YOUNG ADULT;

EID: 59349104779     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458508098268     Document Type: Article

References (11)

1. Cohen SB Emery P Greenwald MW. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-2806.
2. Stüve O Cepok S Elias B. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol 2005; 62: 1620-1623.
3. Petereit H Rubbert A. Effective suppression of cerebrospinal fluid B cells by rituximab and cyclophosphamide in progressive multiple sclerosis. Arch Neurol 2005; 62: 1641-1642.
4. Cree BAC Lamb S Morgan K Chen A Waubant E Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64: 1270-1272.
5. Petereit HF Moeller-Hartmann W Reske D Rubbert A. Rituximab in a patient with multiple sclerosis - effect on B cells, plasma cells and intrathecal IgG synthesis. Acta Neurol Scand 2007; 117: 399-403.
6. Reiber H. External quality assessment in clinical neurochemistry: Survey of analysis for cerebrospinal fluid (CSF) proteins based CSF/serum quotients. Clin Chem 1995; 41: 256-263.
7. Petereit HF Reske D Pukrop R. No effect of intravenous immunoglobulins on cytokine-producing lymphocytes in secondary progressive multiple sclerosis. Mult Scler 2006; 12: 66-71.
8. Felgenhauer K. Theoretische Grundlagen einer Labordiagnostik neurologischer Erkrankungen. In: K Felgenhauer W Beuche, (eds), Labordiagnostik neurologischer Erkrankungen. Stuttgart: Georg Thieme Verlag; 1999. p. 3-12.
9. Ruhstaller TW Amsler U Cerny T. Rituximab: Active treatment of central nervous system involvement by non-Hodgkins lymphoma. Ann Oncol 2000; 11: 374-375.
10. Emery P Fleischmann RM Filipowicz-Sosnowska A. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54: 1390-1400.
11. Regazzi MB Iacona I Avanzini MA. Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogenous clinical settings. Ther Drug Monit 2005; 27: 785-792.